Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eucommia ulmoides bark, commonly known as Du Zhong, is a traditional Chinese medicine (TCM) derived from the dried bark of the Eucommia ulmoides tree. It has been used for over two millennia to treat conditions such as hypertension, osteoporosis, diabetes, and inflammatory disorders. The bark contains a diverse array of bioactive compounds, including lignans (e.g., liriodendrin), iridoids (e.g., aucubin, geniposidic acid), phenolics, and flavonoids. Pharmacological studies suggest that it operates through multiple mechanisms, including the inhibition of pro-inflammatory mediators like COX-2, TNF-α, and IL-6, as well as the modulation of gut microbiota and metabolic pathways. It is typically available as a botanical extract in over-the-counter dietary supplements and traditional herbal formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eucommia ulmoides bark.